Evidence map›Paper›PMID 20051850›Full record

ReviewCurrent opinion in nephrology and hypertension2010

Health-related quality of life outcomes in chronic kidney disease.

Ritu K Soni, Steven D Weisbord, Mark L Unruh

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in nephrology and hypertension, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. High rates of psychological distress, mental health diagnoses and suicide attempts in people with chronic kidney disease in Ireland.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  19. [Quality of life in patients with renal replacement therapy in hemodialysis].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Observational
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ritu K SoniDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
Steven D Weisbord
Mark L Unruh
University of Pittsburgh Medical Center · US

Funding

Impact of Nocturnal Hemodialysis on Sleep Apnea, Sleep Quality & Daytime SymptomsR01DK077785 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI UNRUH, MARK LYNN · 2007 to 2011
$1.3M
Sleep and Daytime Functioning in Chronic Kidney DiseaseK23DK066006 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI UNRUH, MARK LYNN · 2004 to 2008
$710k
NIDDK NIH HHS DK66006NIDDK NIH HHS DK77785NIDDK NIH HHS K23 DK066006NIDDK NIH HHS R01 DK077785
6 · The paper itself

Abstract

purpose of reviewPatients with chronic kidney disease (CKD) endure compromised health-related quality of life (HRQOL). Although the link between HRQOL and increased mortality in patients with end-stage renal disease (ESRD) is well documented, less is known about the relationship between CKD and HRQOL. This article reviews the recent evidence on HRQOL, its correlates and proposed intervention strategies to improve HRQOL in CKD. RECENT

findingsA growing body of literature indicates that various comorbid conditions related to CKD play a substantial role in impaired HRQOL in CKD. Hypertension, both a cause and complication of CKD, negatively affects HRQOL due to associated comorbidities, side effects from antihypertensive medications and awareness of the diagnosis. Anemia has been associated with HRQOL, but concerns about the safety of erythropoietin-stimulating agents (ESAs) have led to more conservative anemia treatment. Frailty, symptom burden and depression are also major contributory factors to HRQOL in CKD. SUMMARY: Certain determinants of HRQOL in CKD, namely anemia and depression, are treatable. Early identification and correction may improve overall well being of patients. Clinical trials are required to demonstrate whether treatment interventions benefit HRQOL in this high-risk population. Furthermore, whether integration of HRQOL assessment into routine clinical practice will improve HRQOL outcomes remains to be determined.

Indexed as

Quality of LifeAnemiaCost of IllnessDepressionHumansHypertension, RenalKidney Failure, Chronic

Identifiers

PMID20051850
PMCPMC2900393
OpenAlexW2090833207

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.